IQVIA Holdings Inc. $IQV Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management S.A. reduced its stake in IQVIA Holdings Inc. by 46.1%, selling 183,471 shares to hold 214,301 shares valued at approximately $33.77 million.
• Several other institutional investors have either increased or initiated their positions in IQVIA, resulting in institutional ownership rising to 89.62% of the company's stock.
• Analysts project a consensus target price of $229.64 for IQVIA, with 18 investment analysts assigning a "Buy" rating and only six giving a "Hold" rating.

Assenagon Asset Management S.A. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 46.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 214,301 shares of the medical research company's stock after selling 183,471 shares during the period. Assenagon Asset Management S.A. owned 0.12% of IQVIA worth $33,772,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IQV. American National Bank & Trust purchased a new position in shares of IQVIA during the 1st quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC raised its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA during the 1st quarter valued at $33,000. Finally, ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 0.3%

IQVIA stock traded up $0.50 during trading hours on Monday, hitting $187.72. The company had a trading volume of 852,803 shares, compared to its average volume of 1,148,829. The firm has a market cap of $31.91 billion, a P/E ratio of 27.17, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $245.20. The company has a 50-day moving average price of $185.35 and a two-hundred day moving average price of $167.16.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the company earned $2.64 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. Mizuho lifted their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Evercore ISI lifted their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Eighteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.